Aging Reversal tests in dogs by 2019 and then in human tests by 2022 if that works

George Church is a Harvard Professor -serial entrepreneur of many multi-million dollar and even billion dollar biotech companies.

This article (interview with George Church) originally appeared in Endpoints. An excerpt is included below, and the complete story can be found here. The interview with George Church at Endpoints is the source of the next three paragraphs in italics, which are statements from George Church.

George Church describes the roadmap for to human aging reversal treatments

We will see the first aging reversal test in dog trials in the next year or two. If that works, human trials are another two years away, and eight years before they’re done. Once you get a few going and succeeding it’s a positive feedback loop.

His company Rejuvenate Bio is actually working on the dog trial now.

The particular dog model we’re using has a heart disease issue. Rejuvenate Bio is still semi-stealth mode, incubator mode, but the trial is not a secret. Dogs are a market in and of themselves. It’s not just a big organism close to humans. It’s something people will pay for. And the FDA process is much faster for dogs than for humans — a little over a year versus nine years or so. We’ll do dog trials and that’ll be a product, and that’ll pay for scaling up in human trials.

FDA does not need to classify aging as a disease in order for them to treat it

The FDA does not need to classify aging as a disease. If you actually have something that causes aging reversal, [the FDA] will approve it. You’ll frame it in conventional terms, but it can have additional benefits. In other words If you have something that fixes one disease problem and happens to fix a bunch of others, you don’t need to put them all on the label. The FDA doesn’t stop you for using things off label or curing two things at once.

Background of George Church – all the companies he has founded or advises

George Church is Professor of Genetics at Harvard Medical School and Director of, which provides the world’s only open-access information on human Genomic, Environmental & Trait data (GET). His 1984 Harvard PhD included the first methods for direct genome sequencing, molecular multiplexing & barcoding. These led to the first genome sequence (pathogen, Helicobacter pylori) in 1994. His innovations have contributed to nearly all “next generation” DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab’s work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics ( Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics ) & synthetic biology / therapeutics ( Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive ). He has also pioneered new privacy, biosafety, ELSI, environmental & biosecurity policies. He is director of an IARPA BRAIN Project and NIH Center for Excellence in Genomic Science. His honors include election to NAS & NAE & Franklin Bower Laureate for Achievement in Science. He has coauthored 453 papers, 105 patent publications & one book (Regenesis).

Editas has a $1.05 billion valuation and George was cofounder. Note : Brian Wang of Nextbigfuture owns some shares of Editas.

George M. Church’s Tech Transfer, Advisory Roles, and Funding Sources (short url for this page:
The first date on each line indicates the year of company founding. (In parentheses are the dates & focus of my involvement.) Founder = F.
Genome Sequencing: (see also Next-gen overview and current genome prices)
Complete Genomics Sunnyvale CA 2006 BGI (2006-present; Next-gen sequencing services)
Danaher-Dover-Polonator Salem NH 2007 (2007-present; sequencing instrument)
Genapsys Redwood City CA 2010 (2010-present) label-free nanosensor array sequencing.
Genia Mountain View, CA (2011-present; then Roche; nanopores)
IBM Yorktown Heights, NY 1911 (2009-2012; DNA Sequencing).
IntelligentBioSystems (IBS, Qiagen) Waltham MA 2006 (2006-2012; Sequencing by Polymerase on beads)
Ion Torrent Guilford, CT 2008 (2009-2013; then LifeTech then Thermo Fisher ; electronic sequencing)
LightSpeed Genomics Sunnyvale CA 2007 (2007-present; high-speed DNA sequencing)
Lynx – Solexa – Illumina Hayward CA 1992; San Diego 1998 (2000-present; multiplex tags)
NABsys Providence, RI 2005 (2010-present) SbH with nanopores.
Noblegen Biosciences Boston MA 2010 (2010-2014; optipore sequencing)
Roswell Biotechnologies San Diego CA 2016 (2016-present; Biomolecular sensors)
Xgenomes Cambridge MA 2014 (2014-present; Analytical optical instruments)

Clinical and Consumer Genomic Diagnostics:
Alacris Pharmaceuticals (Qiagen) Berlin 2008 (2008-present,F; Cancer genomics & systems biology)
Androcyte Florida 2011 (2011-present; Supercentenarians)
AOBiome Cambridge MA 2013 (2013-present; Skin Microbes)
Arivale Seattle, WA 2015 (2015-present; omics and wellness)
CloudHealth Genomics Shanghai 2017 (2017-present; pan-omics)
GPBio Shanghai 2017 (2017-present; DNA chip diagnostics)
Ecoeos San Francisco 2013 (2013-present; Environmental chemicals and omics)
Fitbiomics Boston MA 2015 (2015-present,F; Wellness genomics)
GenePeeks New York NY & Cambridge MA 2014 (2014-present; pre-conception human genetics)
Good Start Genetics Cambridge 2009 (2009-present; Molecular Diagnostics)
Genomera San Francisco 2010 (2010-present; Crowd-sourced Health Insight)
Genos San Francisco, 2016 (2016-present; Personal Genomics)
Logic.Ink San Francisco CA 2015 (2015-present; Data collecting temporary tattoos)
Singlera Genomics La Jolla, CA 2015 (2017-present; Genetic diagnostics)
Twoporeguys Santa Cruz CA 2016 (2016-present; nanopore diagnostics)
Knome, Inc. (then Tute) Cambridge MA 2007 (2007-present,F; Human Genome Sequencing)
Med Data Quest (MDQ) San Diego CA 2015 (2015-present; Clinical genomics)
Pathway Genomics San Diego CA 2008 (2013-present; Personal Genomics)
ReadCoor Boston MA 2014 (2014-present,F; In situ Sequencing)
Searna Boston MA 2015 (2015-present; DNA enrichment diagnostics)
SolveBio New York NY 2012 (2016-present; Computational genomics)
uBiome San Francisco CA 2012 (2016-present; microbiome analysis)
Veritas Genetics Danvers MA 2015 (2015-present,F; Clinical Genomics)
23andme Mountain View CA 2006 (2006-present; personal genomics)

Synthetic Biology, Nucleic Acid Memory, BCI
64-x Boston MA 2017 (2017-present,F; Virus resistant cells)
Alibaba DAMO Academy Hangzhou 2017 (2017-present; DAMO)
Centrillion 2017 (2017-present; DNA synthesis)
EnEvolv Cambridge MA 2011 (2011-present,F; genome engineering)
Enzymatics Beverly MA 2006 (2006-2015; Qiagen Large-scale, high quality enzymes)
Gen9 Cambridge MA 2009 (2009-present,F; Ginkgo, Synthetic Biology)
Genomatica San Diego CA 2001 (2001-present; microbial metabolic models)
Genome Compiler Corp San Francisco CA 2011 (2011-present; Twist, Genome CAD)
GlottaTech 2017 (2017-present,F; DNA synthesis)
GRO Biosciences Cambridge, MA 2016 (2016-present,F; expanded genetic code)
Inari Medford MA 2016 (2016-present,F; agriculture)
INanoBio Tempe AZ 2007 (2017-present; Sensors & sequencing)
Joule Unlimited Cambridge MA 2007 (2007-2015,F, Redrock; SolarFuels)
Memphis Meats New York NY 2015 (2016-present; tissue culture foods)
Nuclera Nucleics Cambridge UK 2014 (2017-present; DNA synthesis)
Synthego Redwood City CA 2016 (2017-present; RNA synthesis)
Synvitrobio San Francisco CA (2015-present,F; In vitro proten synthesis)
Cellinobiotech Cambridge MA 2017 (2017-present; ex vivo protein therapeutic delivery)
The ODIN, Castro Valley CA 2013 (2016-present; Consumer SynBio)

Stem Cells & Therapeutics
AbVitro (then Juno) Boston MA 2010 (2010-present,F; Immunomes).
BioViva Seattle WA 2015 (2015-present; anti-aging gene therapies)
Caribou Biosciences Berkeley CA 2012 (2013-present; Cas9 tools) & Intellia 2014
Celemics Korea 2011 (2011-present; Genome engineering.)
Editas Cambridge MA 2013 (2013-present,F; Cas9 gene therapy)
Egenesis Bio Boston MA 2013 (2013-present,F; Cas9 non-human applications)
Elysium Health New York, NY 2014 (2015-present; Aging & genomic nutritional supplements)
GenEdit Berkeley CA 2015 (2016-present; CRISPR delivery)
HelixNano Cambridge MA 2013 (2016-present; non-viral gene delivery)
Transposagen Lexington KY 2003 (2014-present; Poseida Therapeutics, Hera Testing; Mammalian genome engineering)
Pronutria Cambridge, MA 2011 (2011-2016; Axcella, nutritional synbio)
Recombinetics St. Paul, MN 2008 (2016-present; animal genome engineering)
Rejuvenatebio Boston MA 2015 (2015-present,F; aging-reversal gene therapies)
SeresHealth Cambridge MA 2012 (2012-present; microbiome therapeutics)
Single Cell Technology San Jose CA 2013 (2013-present; Therapeutic antibodies)
Skinome Santa Clara CA 2016 (2016-present; personalized skin care)
Technicolor SA Issy-les-Moulineaux, France 1914 (2012-present; Nucleic Acid Memory)
Verge San Francisco CA 2015 (2015-present; Neurotherapeutics)
Warp Drive Biosynthetics Boston MA 2011 (2011-present,F; Natural product therapeutics)

Publishing and non-profit groups:
Arc Boston MA 2014 (2014-present; Biomed + IT fusion) Boston MA 2009 (2009-present,F; DIYbio)
Centre for Study of Existential Risk (CSER) Cambridge UK 2013 (2013-present; Risk)
Epstein Foundation St. Thomas, VI 2000 (2005-present; cutting edge science & education)
Edge Foundation 1988 (2005-present; science communication)
Future of Life Institute (FLI) Cambridge MA 2014 (2014-present; technology risk management)
Genspace Brooklyn NY 2009 (2011-present; DIY Bio)
MindFirst Foundation Boston MA 2014 (2014-present,F; mental illnesses)
Nature Publishing Group (NPG) 1869 (2005-present; senior editor, MSB)
Open Humans Boston MA 2016 (2016-present,F; open-access human bio-data) Boston MA 2004 (2004-present,F; open-access genome & trait data)
pgEd Boston MA 2006 (2013-present; personal genetics education)
Station for Natural Studies CT,MA 1986 (1986-present,F; genetics)
Scientific American 1845 (2008-present; editorial advisor) Playa Vista CA 1996 (2005-2014; sequencing & energy)

Financial, Investment, Legal Consulting:
ACLU, Supreme Court, Association for Molecular Pathology v. Myriad Genetics (2009; DNA diagnostics)
Amrita GP LLC New York NY 2016 (2016-present; biomedical investment)
Crestwood Advisors LLC Boston MA (Investing)
DeMatteo Monness LLC 1997 (2011-2013; DNA Sequencing)
evalueSCIENCE 2011 (2011-2013; Science and policy advising)
Flagship Ventures Cambridge MA 2000 (2000-present; genomics & informatics)
Georgarage LLC Delaware 2014 (2014-present; tech & biotech)
Guidepoint Global (2009-2013; Genomics technologies)
Gerson Lehrman Group (GLG) (2007-2013; Genomics technologies)
US Supreme Court –Susman Godfrey LLP Amici Curiae Ebay & vs MercExchange LLC (2006; Intellectual Property)

Companies licensing Church lab patents or software:
Agilent Technologies Palo Alto 1999 (2001-present; nucleic acid nanopore sensors)
Affymetrix (Affymax) Palo Alto CA 1993 (1990-2003; Oligonucleotide arrays)
Agencourt (then Beckman Coulter) Beverly MA 2000 (2003-2006; Polony bead sequencing by ligation)
Applied Biosystems Foster City CA 19 81 (2003-2006; via Agencourt, polony bead sequencing by ligation)
Codon Devices (then Gen9) Cambridge MA 2005 (2005-2009,F; Constructive Biology)
Millipore Bedford,MA (1989-1990; multiplex sequencing) and 2009-2013 via EMD
Mosaic Technologies (then Apogent, Illumina) Boston MA 1994 (1993-94 & 2000-2001; DNA diagnostics)
Oxford NanoPore Technologies Kidlington UK 2005 (2008)
Pyrosequencing (also Biotage – 454) Stockholm 2000 (2001-2005; modified dNTPs for array sequenc

SOURCE- George Church, Elysium Health, Rejuvenate Bio